Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis
| Autor: | Ya Meng, Sandrine I. Samson, Phillip S Leventhal, Rosalind Hollingsworth, Bruce T. Seet, Victoria Landolfi, Camille Salamand, David A. Greenberg |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Influenza vaccine Immunology Immunocompromised Host 03 medical and health sciences Immunogenicity Vaccine Influenza A Virus H1N1 Subtype 0302 clinical medicine Influenza Human Drug Discovery Humans Medicine 030212 general & internal medicine Elderly adults Aged Randomized Controlled Trials as Topic Pharmacology business.industry Influenza A Virus H3N2 Subtype Immunogenicity Vaccination virus diseases Virology 030104 developmental biology Influenza Vaccines Meta-analysis Molecular Medicine business |
| Zdroj: | Expert Review of Vaccines. 18:295-308 |
| ISSN: | 1744-8395 1476-0584 |
| DOI: | 10.1080/14760584.2019.1575734 |
| Popis: | Introduction: High-dose trivalent, inactivated, split-virus influenza vaccine (IIV3-HD) has been available in the US since 2009 for adults aged ≥ 65 years. To better understand how IIV3-HD provides improved protection against influenza, we systematically reviewed clinical studies comparing immune responses to IIV3-HD and standard-dose trivalent vaccine (IIV3-SD). Areas covered: The primary objective was to determine the relative hemagglutination inhibition (HAI) antibody response of IIV3-HD vs. IIV3-SD in adults aged ≥ 65 years. Based on seven randomized studies including more than 18,500 adults aged ≥ 65 years, combined HAI geometric mean titer (GMT) ratios (95% confidence interval) approximately 1 month post-vaccination were 1.74 (1.65–1.83) for influenza A/H1N1, 1.84 (1.73–1.95) for influenza A/H3N2, and 1.47 (1.36–1.58) for influenza B. HAI GMT ratios in these studies were similar irrespective of sex, older age (≥ 75 years), frailty, and underlying conditions. Trends were similar for A/H3N2 neutralization and anti-neuraminidase antibody titers. In immunocompromised individuals, HAI GMT ratios were mostly > 1. Expert opinion: In agreement with its improved efficacy and effectiveness, IIV3-HD is consistently more immunogenic than IIV3-SD in adults aged ≥ 65 years. IIV3-HD also appears more immunogenic in immunocompromised individuals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|